Orexo sells its peptide technology
Orexo AB has sold the rights for its cell-penetrating peptide technology, CPP. "Orexo's strategy is to regularly evaluate and analyze both its products and technologies," says Zsolt Lavotha, President and CEO of Orexo AB. "Today, we have a portfolio of several product candidates at different stages of development, all of which are based on our internally developed and patented technology platforms. Our business model is based on short development times and low development risk. Our assessment is that, while promising, Orexo's cell-penetrating peptide technology (CPP) is in an early research phase. Accordingly, the sale of this technology is a natural step for Orexo at this time," concludes Zsolt Lavotha.
Purchase price was 9,5 MSEK. The joint purchasers are professor Ülo Langel and Dr. Mattias Hällbrink through company.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.